EpiDisease
EpiDisease is a biomedical company focused on developing cutting-edge in vitro diagnostic (IVD) tools that combine genetics, epigenetics, and artificial intelligence to manage complex diseases and improve patient outcomes globally. Their product portfolio leverages epigenetic biomarkers such as DNA methylation, histone modifications, and microRNAs to enable precision medicine approaches, including early diagnosis, prognosis, and personalized treatment strategies. The company emphasizes rigorous scientific methodology, continuous innovation, and collaborative work with medical professionals and patient associations. Based in Paterna, Spain, EpiDisease integrates advanced mass spectrometry and immunological techniques to analyze epigenetic modifications, aiming to transform healthcare through improved diagnostic accuracy and patient care.
EpiDisease
EpiDisease is a biomedical company focused on developing cutting-edge in vitro diagnostic (IVD) tools that combine genetics, epigenetics, and artificial intelligence to manage complex diseases and improve patient outcomes globally. Their product portfolio leverages epigenetic biomarkers such as DNA methylation, histone modifications, and microRNAs to enable precision medicine approaches, including early diagnosis, prognosis, and personalized treatment strategies. The company emphasizes rigorous scientific methodology, continuous innovation, and collaborative work with medical professionals and patient associations. Based in Paterna, Spain, EpiDisease integrates advanced mass spectrometry and immunological techniques to analyze epigenetic modifications, aiming to transform healthcare through improved diagnostic accuracy and patient care.
TL;DR
Founded: 2014
Headquarters: Paterna (Valencia), Spain
Focus: Epigenetics-based in vitro diagnostics (IVD) combining genetics, epigenetics and AI
Notable products: ScoliGEN / ScoliMIR (adolescent idiopathic scoliosis), HistShock (sepsis)
Funding: Seed round (Jul 26, 2018) — lead investor: Fundación Botín
Company Overview
Problem Domain
Diagnostics for complex diseases using epigenetic biomarkers and bioinformatics/AI
Founded
2014
Industry
Biotechnology
Funding Track Record
Investor Signal
“Fundación Botín participated as lead investor in the disclosed seed round”